Testing targeted drugs for rare cancers based on tumor gene changes
Tests imatinib, trametinib or dabrafenib in people with rare cancers having treatable gene changes.
Plain-language title generated from the registry record
Registry title: Precision Cancer Therapy in Rare Cancers
Key facts
- Where
- Oslo, NorwaySee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 99 years old?
Source: NCT06119789, who can take part
Where in Norway
- Oslo University HospitalOslo, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oslo University Hospital
- Trial code
- NCT06119789
- Record updated
- 26 March 2025
- Original description
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.Read full original descriptionShow less
The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers
Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.
In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.
Inclusion: ECOG 0-2,; identified biomarker,; reasonable biochemistry.
Exclusion: serious other diseases; ECOG 3-5.